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Abstract A retrospective chart review was performed of all
patients with juvenile idiopathic arthritis (JIA) followed at
our clinic who had an intra-articular steroid injection
between 1 January 1997 and 31 December 2001. The aim
of the study was to evaluate the outcome of intra-articular
steroid injections (iaS) and determine prognostic factors.
During the study period, 202 iaS were performed in 60
patients, of whom 37 had oligoarticular JIA, 15 had
polyarticular, rheumatoid factor-negative JIA and four each
had systemic and enthesitis-related JIA. The median
duration of remission was 23.1 months (range: 0–69
months). At last follow-up, 103 joints (51%) of 47 patients
were still in remission after a median follow-up time of 28
months (range: 1–69 months). For the total cohort, the
remission was longer for wrist and finger joints [risk ratio
(RR): 0.2], with concomitant treatment with methotrexate
(RR: 0.28) and for enthesitis-related arthritis (RR: 0.34).
For the group of knee joints, remission was longer with
concomitant treatment with methotrexate (RR: 0.37), with
triamcinolone hexacetonide (RR: 0.77) and with general
anaesthesia for the procedure (RR: 0.56). Mild side effects
were observed in 45 iaS (22.3%), and skin atrophy occurred
at the injection site in 2% of injections, but no major
adverse event occurred in our cohort. In conclusion, iaS is a
safe procedure with a median duration of remission of 23.1
months. The remission was longer in the joints of the upper
extremity, with concomitant treatment with methotrexate
and when the injection was performed under general
anaesthesia.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease of childhood, with a prevalence between
7 and 400 per 100,000 children [10]. Seven subgroups of
JIA have been defined by the International League of
Associations for Rheumatology (ILAR) [15], with oligoar-
ticular JIA being the most common. Recent studies on the
long-term outcome of affected children show that JIA will
often extend into adulthood [6, 11, 13] and may cause
severe joint destruction if the arthritis is uncontrolled for
longer periods of time [13]. New drugs for the treatment of
arthritis, especially the group of TNFα-blockers, are
increasingly used to treat JIA and have significantly
improved the quality of life of affected children [9, 18].
However, the higher number of treatment options increases
the need to assess their respective effectiveness and safety
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in order to choose the best suited therapy for an individual
patient.
Intra-articular corticosteroid injection (iaS) is a treatment
option for patients with active arthritis in a small number of
joints [7]. It is recommended as the treatment of choice for
oligoarticular JIA but may also be used in cases where only
a few joints remain actively inflamed during a treatment
with systemic disease-modifying drugs such as methotrex-
ate [4, 14, 19]. The duration of remission after iaS varies
widely [1, 2, 14]. The peak incidence of oligoarticular JIA
is at preschool age, and small children will usually need
general anaesthesia for joint injections. Possible complica-
tions occurring after iaS include infections, local skin
atrophy or hypopigmentation, intra- or periarticular calcifi-
cations or avascular necrosis of the epiphyseal bone [8, 12,
14]. A knowledge of factors influencing the prognosis of
iaS will help to select adequate treatment options and
improve counselling of parents and patients.
The aim of our study was to evaluate the efficacy and
safety of intra-articular steroid injections performed at our
centre and to examine factors influencing the outcome of
this procedure in a retrospective manner.
Patients and methods
The Paediatric Rheumatology database at the University
Children’s Hospital of Zurich was searched for patients with
JIAwho had undergone iaS between 1 January 1997 and 31
December 2001. The charts of all 67 patients (288 injections)
found were reviewed. Seven patients were excluded: three
patients with eight injections performed in outside clinics,
and two patients (four injections) who were followed at an
outside clinic after the injections had been performed at our
institution. Two patients with severe systemic JIAwith a total
of 74 joints injected for temporary relief of their refractory
polyarticular arthritis were excluded from the analysis
because the high number of injections in these two patients
with extremely resistant disease skewed the analysis. Of the
remaining 60 patients, the following data were collected: date
of birth, gender, date of diagnosis of JIA, JIA subtype, results
of anti-nuclear antibody (ANA), human leucocyte antigen
(HLA) B27 and rheumatoid factor (RF) testing, diagnosis of
uveitis, date of steroid injection, location of the injected joint,
medication and dose injected, concomitant medication at the
time of injection, date of arthritis relapse in the injected joint
(if applicable), type of anaesthesia used (if applicable), side
effects, such as nausea/vomiting, paradoxical reaction to
sedation, increased appetite, flushed cheeks, local infections
or atrophy/hypopigmentation at the site of injection. The end
point of study follow-up was 31 October 2002.
Triamcinolone hexacetonide is used at our clinic as the
drug of choice for intra-articular steroid injections. Due to
production shortfalls, this drug was not always available
during the study period, and triamcinolone acetonide was
used as a replacement medication from 1 September 1997
until 31 January 1999 and from 1 March to 31 October
2000. The dose of triamcinolone acetonide used was double
the amount (in milligrams) of triamcinolone hexacetonide.
For children with a body weight of ≥40 kg, the dose of
triamcinolone hexacetonide injected was 40 mg in big
joints (knee, shoulder, hip), 20 mg in medium joints (wrist,
elbow, ankle, subtalar) and 5 mg in finger and toe joints.
Children with a body weight between 20 and 40 kg would
receive 75% of these doses, and children with a body
weight <20 kg would receive 50% of these doses. All
injections were performed by the same paediatric rheuma-
tologist (RKS). Injections into hips were performed with
ultrasound guidance, while injections into subtalar and
midfoot joints were performed using fluoroscopy to control
for correct position of the needle. Standard clinical routine
consisted of asking all patients and their parents to keep the
injected joint as quiet as possible for a 24-h period after
injection.
Remission of arthritis in a joint was defined as the
absence of signs of inflammation, such as capsular (soft
tissue) swelling, effusion or the combination of tenderness
and pain on motion. A joint with presence of any of the
aforementioned signs of inflammation was considered to be
actively inflamed.
Statistical analysis was performed using JMP IN 5.1
programme (SAS Institute, Cary N.C.) . We used the chi-
square test and survival analysis (Kaplan Meier) with log
rank/Wilcoxon to assess for differences among the groups.
Factors significantly associated with the duration of
remission were then tested in a Cox Proportional Hazards
regression model.
The study was approved by the Institutional Review
Board.
Results
The 60 patients included in our study had 202 joint
injections on 106 occasions (mean: 1.9 injections per
occasion; range: 1–12). Table 1 presents the patients'
characteristics and distribution of joints. No patients with
psoriatic JIA or polyarticular, RF-positive JIA underwent
joint injections during the study period, and no patient
tested RF-positive. The distribution of joint types was
highly significantly different among subtypes of JIA (chi-
square p<0.0001). For the duration of remission according
to joint type, see Table 2. Sixteen patients (26.7%) had only
one joint injection, 19 patients (31.7%) had several joints
injected at one occasion (mean: 2.3 joints; range: 2–12) and
25 patients (41.7%) had injections performed on several
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occasions, with 49 repeated injections (24.3% of all
injections) performed into a previously injected joint. In
total, 153 different joints were injected, with 118 joints
(77.1%) injected once, 25 joints (16.3%) injected twice, six
joints (3.9%) injected three times and four joints (2.6%)
injected four times.
One or more concomitant medications were used during
165 iaS (81.7%), including non-steroidal anti-rheumatic
drugs (NSAR) (141 iaS; 69.8%), methotrexate (66 iaS;
32.7%), systemic corticosteroids (16 iaS; 7.9%) and salazo-
pyrine (one iaS). One hundred and fifty one (74.7%) iaS
were performed under general anaesthesia, 18 (8.9%) in
sedation with midazolam/nalbuphine, eight (4%) with local
anaesthesia and 25 (12.4%) without anaesthesia. Table 3
shows how the distribution of joints injected under the dif-
ferent types of anaesthesia differed significantly (chi-square
p=0.014). Triamcinolone acetonide was used for 87/202 iaS
(43.1%), triamcinolone hexacetonide for 108/202 (53.5%)
Table 1 Patients’ characteristics
Patient characteristics Total JIA subtype
Oligoarticular Polyarticular
RF negative
Systemic Enthesitis-related
Total number of patients (percentage of total) 60 37 (61.6) 15 (25) 4 (6.7) 4 (6.7)
Female gender (percentage of total) 42 (70) 27 (73) 13 (86.7) 2 (50) 0
Mean age at diagnosis in years (range) 6.4 (1.1–15.0) 6.1 (1.1–15.0) 6.5 (1.6–13.8) 3.0 (1.8–5.8) 11.6 (11.0–12.1)
Diagnosis of uveitis (percentage of total) 9 (15) 7 (18.9) 2 (13.3) 0 0
ANA positive (percentage of total) 39 (65) 26 (70.3) 11 (73.3) 2 (50) 0
Mean age at iaS in years (range) 8.5 (1.1–16.1) 7.7 (1.1–14.9) 9.2 (1.8–16.1) 9.4 (8.6–10.9) 12.3 (11.2–12.9)
Number of patients with iaS on more than
one occasion
26 (43.3) 16 (43.2) 6 (37.5) 3 (75) 1 (25)
Total number of joints injected during study
(percentage of total)
202 102 (50.5) 60 (29.7) 21 (10.4) 19 (9.4)
Number of joints with repeated iaS
(percentage of total)
49 (24.3) 29 (28.4) 13 (21.7) 7 (33.3) 0
Mean number of joints injected per patient
(range)
3.4 (1–12) 2.8 (1–9) 4.1 (2–8) 5.25 (3–7) 4.2 (1–12)
ANA, Anti-nuclear antibodies; RF, rheumatoid factor; iaS, intra-articular steroid injection; JIA, juvenile idiopathic arthritis
Table 2 Duration of remission according to joint type
Joint type Number
of joints
injected
Number of joints
with arthritis flare
after iaS (percent)
Mean/median
duration of
remission until flare
in months (range)
Number of joints in
ongoing remission
at end of study
(percent)
Mean/median
follow up time of
joints with ongoing
remission in
months (range)
Risk ratio for
relapse in the
Cox regression
model
All joints 202 99 (49) 6.9 / 6.0 (0–30) 103 (51) 29.1/ 28.0 (1–69)
Knee 108 55 (50.9) 8.0 / 6.0 (0–27) 53 (49.1) 27.2 /24.0 (1–69) 1.05
Ankle 29 19 (65.5) 4.5 / 3.0 (0–13) 10 (34.5) 18.2 / 14.0 (1–39) 1.88
Wrist 27 11 (40.7) 7.3 / 6.0 (0–24) 16 (59.3) 31.6 / 31.0 (13–52) 0.74
Finger/toe 20 4 (20) 8 / 5.5 (4–17) 16 (80) 40.3 / 46.0 (18–66) 0.2
Subtalar 5 4 (80) 3.5 / 1.5 (0–11) 1 (20) 13 2.58
Shoulder 4 2 (50) 18 / 18 (6–30) 2 (50) 25 /25
Elbow 3 1 (33.3) 2 2 (66.7) 39.5 / 39.5 (12–67)
Hip 3 0 n.a. 3 (100) 28.7 / 13.0 (13–66)
Midfoot 3 3 (100) 1 / 0 (0–3) 0 n.a.
JIA subtype
Oligoarticular 102 67 (65.7) 6.5 / 5 (0–27) 35 (34.3) 25.1 / 24 (1–69)
Polyarticular RF
negative
60 21 (35) 7.3 / 6 (2–24) 39 (65) 27.2 / 23 (1–66)
Systemic 21 10 (47.6) 9.9 / 8 (0–30) 11 (52.4) 39.1 / 32 (25–67)
Enthesitis-related 19 1 (5.3) 12 18 (94.7) 35.2 / 46 (11–46)
n.a., Not applicable
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iaS and for 7 iaS the medication used was not recorded. Al-
though the use of triamcinolone acetonide or triamcinolone
hexacetonide was dependent only on availability of the drug,
the distribution of joints injected with these two medications
differed significantly (chi-square p=0.036; Table 3).
In a first analysis, the outcome of all iaS was evaluated
using a survival (Kaplan-Meier) analysis. Table 4 presents
the factors tested and their respective association with the
duration of remission.
In a second analysis, the outcome of the 108 knee joints
was analysed for risk factors, as this was the largest ho-
mogeneous group of joints injected in our cohort. Table 4
presents the factors significantly associated with a longer
duration of remission in knee joints.
Minor side effects of the treatment were recorded for
26 patients and 45 injections (43.3 and 22.3%, respectively).
These were related to anaesthesia in eight patients/15 injections
(13.3/7.4%) [six nausea/vomiting, three paradoxical reac-
tion (agitation) following sedation]. Possible systemic ef-
fects of corticosteroids were recorded in seven patients/16
injections (11.7/7.9%) (one flushed cheeks, three increased
appetite, three mood changes) and local side effects to
steroid injections were recorded in 12 patients/14 injections
(20/6.9%) (14 skin atrophies combined with hypopigmen-
tation at the injection site in 7/14). Ten of the 14 skin
atrophies (71.4%) and five of the seven hypopigmentations
(71.4%) observed were transient, with complete resolution
occurring during the study period leaving a rate of 2% (4/
202 injections) of local long-term side effects. The
occurrence of skin atrophy or hypopigmentation did not
correlate with joint type, age at diagnosis, age at injection
or type of anaesthesia used. No major side effects, such as
infections, skin necrosis or avascular necrosis related to the
steroid injections, were observed in our cohort.
Table 4 Factors tested for association with duration of remission
Risk factor tested Significance of association with duration of remission
Total group Knee joint group
Kaplan Meier Cox regression Kaplan Meier Cox regression
Subtype of JIA p<0.0001* p=0.019*, RR 0.34 p=0.77
Concomitant treatment with methotrexate p<0.0001* p=0.0001*, RR 0.28 p=0.001* p=0.009*, RR 0.37
Larger number of joints injected at the same time p<0.0001* n.s. p=0.004* p=0.18, RR 0.84
Type of joint injected p=0.0003* p=0.014*, RR 0.2 n.a.
Joint of upper extremity p=0.0034* n.s. n.a.
Diagnosis of uveitis p=0.14 p=0.54
Negative ANA p=0.007* n.s. p=0.39
Presence of HLA B27 p=0.017* n.s.
Absence of skin atrophy at injection site p=0.02* n.s.
Time elapsed from diagnosis until injection p=0.12
Age at diagnosis p=0.19 p=0.54
Age at injection p=0.2 p=0.37
Gender p=0.44 p=0.25
Use of triamcinolone hexacetonide p=0.79 p=0.025* p=0.04*, RR 0.77
General anaesthesia p=0.9 p=0.01* p=0.049*, RR 0.56
Concomitant treatment with NSAR p=0.99
*Significant at p≤0.05
RR, Risk ratio; HLA B27, human leucocyte antigen B27; NSAR, non-steroidal anti-rheumatic drugs
Table 3 Distribution of
medication and type of
anaesthesia used
a The triamcinolone type used
was not recorded for one knee
and four finger/toe joints
Number (percentage)
of joints injected using
Joint type
Knee
(n=108a)
Wrist
(n=27)
Ankle
(n=29)
Finger/toe
(n=20a)
Subtalar
(n=5)
Triamcinolone acetonide 46 (42.6) 13 (48.2) 12 (41.4) 13 (65) 1 (20)
Triamcinolone hexacetonide 61 (56.5) 14 (51.9) 17 (58.6) 3 (15) 4 (80)
General anaesthesia 69 (63.9) 24 (88.9) 25 (86.3) 20 (100) 5 (100)
Sedation 13 (12.0) 3 (11.1) 1 (3.4) 0 0
Local/no anaesthesia 26 (24.1) 0 3 (10.3) 0 0
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Discussion
Intra-articular steroid injections are commonly used for
treatment of children with JIA and are considered the
treatment of choice for oligoarticular joint involvement [4].
In our cohort iaS was a safe and very effective treatment
with a median time of remission of 23.1 months.
The range of duration of remission after iaS varied
widely in our cohort, but other investigators have had the
same experience [2, 14, 16]. The current body of
knowledge on factors influencing outcome is limited. In
addition to the well-documented effect of the type of
triamcinolone used [5, 23], high erythrocyte sedimentation
rate [16] and the subtype of arthritis [2] have been shown to
be of importance. In our cohort, there was a significant
difference in the duration of remission between the different
joints, with a significantly longer remission in joints of the
upper extremities, followed by the knees. The question that
arises is whether weight-bearing may have an influence on
the duration of remission in joints after iaS. Trauma- and/or
stress-induced arthritis have been reported, especially in
cases of psoriatic arthritis [17, 20]. However, the question
of whether weight-bearing joints are at higher risk for
relapse of arthritis or which other factors might be
responsible for this result remains unclear. Breit et al. [2]
found that the subtype of juvenile arthritis was more
important than the type of joint injected, and they did not
find a difference in the duration of remission between joints
of the upper and lower extremities. It is difficult to compare
our study with the study of Breit et al. as they used a
scoring system to measure improvement of the arthritis
rather than the duration of complete remission after
injection as we did in the present study. The subtype of
JIA was a highly significant risk factor in our total cohort.
However, this factor was no longer significantly associated
with the duration of remission when the analysis was
restricted to the more homogeneous group of knee joints.
This result is in agreement with the findings of other
authors [5, 16]. Our results from the knee joint cohort
suggest that the difference in outcome among subtypes of
JIA found in our total cohort may reflect the highly
significant difference in the distribution of joints injected
in these subgroups. However, we can not exclude the
possibility that the subtype of JIA may be of importance for
the outcome of iaS in joints other than knees.
Concomitant use of methotrexate was the strongest
predictive factor in our study and was highly significantly
associated with a longer duration of remission both in the
total cohort and in the subgroup of knee joints, whereas use
of NSAR was not. Allen et al. [1] found that a higher dose
of NSAR was significantly associated with a longer
duration of remission after iaS, whereas most other authors
do not comment on the influence of concomitant medica-
tion on the outcome of iaS [2, 5, 16]. We feel that our
results confirm that iaS into residual joints during treatment
with methotrexate is very effective and may be a viable
alternative to TNFα-blocker use if only a few joints remain
active with methotrexate alone. However, this hypothesis
would have to be tested in a prospective study.
Several studies have shown a superior efficacy of
triamcinolone hexacetonide compared to triamcinolone
acetonide in patients with JIA [5, 23]. We found a
significantly better efficacy of triamcinolone hexacetonide
when we looked at the subgroup of knee joints but not for
the total group. However, we must point out that our study
is retrospective and was not designed to look for a
difference in these two medications. Although the total
number of joints injected with each type of triamcinolone
was comparable, the joint types were significantly different
among the groups. Our results confirm the findings of the
superiority of triamcinolone hexacetonide over triamcino-
lone acetonide for the knee joints, but in the total group this
effect was probably confounded by the difference in
response related to the type of joint injected.
The superiority of general anaesthesia over other types
of pain reduction for the procedure was an unexpected
result in the subgroup analysis of the knee joints. We were
not able to assess the effects of anaesthesia type for other
joints as the number of joints other than knees injected
without general anaesthesia was too small for analysis. One
might argue that this result only reflects differences in
injection technique as it is technically easier to perform
arthrocentesis in an anaesthetized child. However, the knee
joint is not only the joint most commonly injected in our
cohort, it is probably also the joint of the human body most
easily accessible for injection. Although we cannot rule out
differences in injection technique as a possible explanation
for this unexpected result, other factors associated with the
use of general anaesthesia for the injection must be
considered. Several studies in adult patients with rheuma-
toid arthritis were able to show that rest of the injected joint
for 24–72 h improves the outcome of iaS in knee joints [3,
22] but not in wrists [21]. No similar study in children has
been conducted to our knowledge. Although we generally
advise parents and children to rest the injected joint for
24 h after the injection, we are not able to objectively con-
trol the compliance to this advice. We therefore conclude
that further studies are needed to assess the impact of
general anaesthesia and bed rest on duration of remission
after iaS.
The side effects of the procedure were mostly mild and
transient, although they were not uncommon in our cohort.
Most of these were related to side effects of the anaesthetic
medication used or to transient systemic effects of the
steroids injected. Hypopigmentation and skin atrophy at the
injection site have been reported earlier [8, 14]. In
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agreement with most other authors, we were able to
demonstrate a high rate of complete resolution of these
local corticosteroid side effects over time.
Our study is limited by a heterogeneous patient cohort
and the variety of different joints injected in each patient.
For some infrequently injected joints, factors influencing
the outcome of the procedure could not be tested because of
the small numbers, yet these joints may have influenced the
overall result of our study. We attempted to compensate for
this shortcoming with the analysis of the more homoge-
neous group of knee joints.
In conclusion, we have shown that intra-articular
corticosteroid injection is a safe and effective treatment
for patients with JIA. It is especially efficacious in joints of
the upper extremities and knees and in combination with
methotrexate. Although side effects are quite common, they
are usually mild and do not require interventions.
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